Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 113, Issue 31, Pages E4558-E4566Publisher
NATL ACAD SCIENCES
DOI: 10.1073/pnas.1608319113
Keywords
bromodomain inhibitor; TRIM33; JQ1; drug resistance; TGF-beta
Categories
Funding
- NCATS NIH HHS [UL1 TR001863] Funding Source: Medline
Ask authors/readers for more resources
Bromodomain and extraterminal domain protein inhibitors (BETi) hold great promise as a novel class of cancer therapeutics. Because acquired resistance typically limits durable responses to targeted therapies, it is important to understand mechanisms by which tumor cells adapt to BETi. Here, through pooled shRNA screening of colorectal cancer cells, we identified tripartite motif-containing protein 33 (TRIM33) as a factor promoting sensitivity to BETi. We demonstrate that loss of TRIM33 reprograms cancer cells to a more resistant state through at least two mechanisms. TRIM33 silencing attenuates down-regulation of MYC in response to BETi. Moreover, loss of TRIM33 enhances TGF-beta receptor expression and signaling, and blocking TGF-beta receptor activity potentiates the antiproliferative effect of BETi. These results describe a mechanism for BETi resistance and suggest that combining inhibition of TGF-beta signaling with BET bromodomain inhibition may offer new therapeutic benefits.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available